Next-Gen Oral SERD Cuts Recurrence Risk in Early Breast Cancer

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators reported phase III results showing that estrogen receptor-selective oral giredestrant (SERD) significantly reduced the risk of recurrence compared with standard…